Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02319525 · ClinicalTrials.gov registry record · NA

Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus

A NA study, sponsored by University of Alabama at Birmingham.

Completed
Registry status
NA
Development phase
301
Enrollment target

NCT02319525: Completed NA study, sponsored by University of Alabama at Birmingham.

NCT02319525 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 301 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02319525, a NA study, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
NA
Development phase
301 participants
Enrollment target

Study Summary

The study will compare the efficacy of the usual education materials to individualized computerized decision guide on decision conflict of patients with lupus nephritis making treatment decisions regarding immunosuppressive therapies.

Primary Outcome

Patient self-administered, validated measure of decisional conflict, most commonly used as the primary outcome in RCTs of decision aids (change score). The score ranges from 0 (no decisional conflict) to 100 (extreme decisional conflict). Decisional conflict represents a state of uncertainty about a choice or course of action and is more likely in situations involving high-stakes choices with important potential gains and losses, value tradeoffs in selecting a choice or a course of action (vs. t

Interventions

  • OTHER Computerized patient decision-aid
  • OTHER Usual care (lupus pamphlet)

Trial Details

FieldValue
Enrollment Target 301 participants
Start Date 2014-01
Est. Completion 2016-12
Phase NA
University of Alabama at Birmingham

1,160 total trials

What the finished NCT02319525 record still lists

NCT02319525 is an interventional study that assigns participants to a tested intervention. The registered 301 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).

The record links to 0 conditions, and to 2 interventions - of which Computerized patient decision-aid is the first listed.

NCT02319525 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02319525 about?

NCT02319525 is a clinical study titled "Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus". The study will compare the efficacy of the usual education materials to individualized computerized decision guide on decision conflict of patients with lupus nephritis making treatment decisions regarding immunosuppressive therapies.

What is the current status of trial NCT02319525?

This trial is currently completed. It is a NA study. The enrollment target is 301 participants. The study started on 2014-01. Estimated completion is 2016-12.

What interventions are being tested in trial NCT02319525?

The interventions under investigation include: Computerized patient decision-aid (OTHER), Usual care (lupus pamphlet) (OTHER).

Who is sponsoring clinical trial NCT02319525?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02319525's enrollment target sits among peer trials

301 330th of 2000 higher than 1,671 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05005975 · 301 participants · Phase 3

    Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

  • NCT05722561 · 302 participants · Phase 2

    E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder

  • NCT06015737 · 302 participants · Phase 3

    A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

  • NCT07176273 · 302 participants · NA

    Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02319525, the US trial registry maintained by the National Library of Medicine. NCT02319525 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.